Background: Most neuroendocrine tumors express chromogranin A (CgA). The posttranslational processing of neuroendocrine proteins such as CgA is often specific for the individual tumor. To cope with this variability and improve tumor diagnosis, we developed a processing-independent analysis (PIA) method to measure the total CgA product. Methods: For PIA, samples underwent trypsin treatment followed by measurement of CgA by the "CgA(3403)" assay, in which the antiserum binds an epitope starting at amino acid 340 of CgA and including amino acid residues located in the C-terminal direction. The diagnostic accuracy of the CgA PIA and 3 sequencespecific assays for CgA were evaluated on plasma samples from patients with neuroendocrine tumors and small-cell lung carcinomas. Furthermore, we investigated whether the CgA plasma concentrations correlated with the tumor burden. Results: Size-exclusion chromatography of plasma showed that CgA immunoreactivity mainly consisted of high-molecular-weight forms, indicating that neuroendocrine tumors may secrete large amounts of poorly processed CgA. Accordingly, trypsination of plasma from 54 patients with neuroendocrine tumors or smallcell lung carcinomas increased the CgA(3403) immunoreactivity up to 500-fold. Both the CgA(3403) assay and the PIA measured significantly higher plasma concentrations in patients with very extensive disease than in patients with less widespread disease. The diagnostic
cytoma and healthy individuals. In addition we investigated whether the CgA plasma concentrations correlate with the tumor burden.
Materials and Methods nomenclature
The specificity of the assays (antisera) is described by indicating the N-or C-terminal amino acid of the hapten as recognized by the antiserum. Thus, "CgA (3403) assay" indicates that the antiserum employed in this assay binds an epitope that starts at amino acid number 340 of CgA and includes amino acid residues located in the C-terminal direction.
immunoassays
Index test: development of a PIA for human CgA. An amino acid sequence of 6 -8 amino acid residues is selected for immunization. It should not undergo posttranslational modifications, and it must be located between suitable (tryptic) cleavage sites. The sample to be assayed is preincubated with trypsin. In addition to exposing the epitope, the endoproteolytic cleavage ensures that equalsized fragments with lengths similar to the assay calibrator are released so that proprotein and final products are quantitated with equimolar potency (5, 7, 9, 11 ) . The CgA(340 -348) sequence neighbors suitable tryptic cleavage sites, i.e., trypsination will release the CgA fragment Leu 340 -Lys 355 . Trypsin treatment (described below) and subsequent quantification by the CgA(3403) assay thus provide an estimate of the total CgA mRNA translation product, i.e., total CgA. Furthermore the CgA (340 -348) sequence does not undergo posttranslational modifications.
Sequence-specific CgA (340 -348) RIA. We previously developed an RIA specific for the N-terminus of the sequence CgA(340 -348) [CgA(3403)], adjacent to a dibasic site (Lys 338 Arg 339 ) in the midportion of hCgA (using antibody 95058) (15 ) . The interassay CVs of replicate samples for the CgA(3403) assay were 21% at 15 pmol/L and 18% at 62 pmol/L. (1) (2) (3) (4) (5) (6) (7) (8) (9) and amide. We previously developed an RIA specific for the N-terminus of human CgA [using antibody 94188) (CgA (13) ] (15 ) . The CgA(4301) assay (using antibody 871w-1) is specific for the amidated C-terminus of pancreastatin (16 ) . The antiserum reacted fully with the synthetic peptides hCgA(273-301) amide and hCgA(250 -301)amide.
Sequence-specific RIAs for CgA

plasma samples
Blood samples were collected as previously described (15 ) . All plasma samples were analyzed with the CgA(13), CgA(4301 amide), and CgA(3403) assays. Furthermore, the samples were analyzed with the index test, i.e., treated with trypsin, as described below, and subsequently analyzed with the CgA(3403) assay.
enzymatic treatment of plasma samples
For trypsin cleavage, equal volumes of plasma and 0.1 mol/L sodium phosphate buffer (pH 7.5) containing 2.0 g trypsin/L were incubated at room temperature for 30 min. For enzymatic cleavage of column fractions a trypsin concentration of 0.2 g/L was used. The enzymatic reaction was terminated by boiling for 10 min. Parallel control experiments were performed by omission of trypsin from the sodium phosphate buffer.
size-exclusion chromatography of plasma samples
Plasma samples from carcinoid tumor patients (150 -200 L) were applied to a Superose 12 HR column. Chromatography was performed as described previously (15 ) . The column was calibrated with synthetic hCgA(250 -301 amide) and an hCgA (340 -372) fragment purified from a midgut carcinoid tumor. The identity of the fragment was established by mass spectrometry analysis. The fractions were analyzed, before and after tryptic cleavage, with the CgA(3403) assay.
reference test: histological classification of neuroendocrine tumors and sclc
For tumor patients histopathological analysis was performed as a routine test for diagnosis and classification. Biopsy material, surgical or coarse-needle biopsy specimens, was fixed in formalin and paraffin-embedded. The tumors were immunostained with a panel of antibodies to general neuroendocrine markers (e.g., CgA and synaptophysin) as well as specific hormones. The microscopy report included a general morphological description; immunohistochemical profile; mitotic rate; vascular, perineural, or lymphatic invasion; infiltration of surrounding tissues; lymph node status; and distant metastases (17) (18) (19) (20) months after the reference test was performed. The patients did not receive chemotherapy in the time interval between the 2 tests, and for all these patients it was shown by computer tomography and/or ultrasonography that tumor tissue was present at the time of plasma sample collection.
For the 6 pheochromocytoma patients the reference test was performed between August 1995 and September 1996. In these patients the plasma samples used for index tests were drawn shortly before surgery and reference testing.
The reference tests on the 21 SCLC patients were made between May 1991 and November 1992, and the plasma samples for index tests were collected shortly after the reference test was performed. No treatment (chemotherapy or operation) took place between the 2 tests.
The patient characteristics (age, sex, and severity of disease) are shown in Table 1 .
The study was approved by the local ethics committee and informed consent was obtained from all patients (KF01-393/95, KF01-352/96, KF01-290/97, KF01-014/98).
Plasma samples from normal subjects. To establish reference intervals for the CgA(3403) and CgA(3403) posttryptic assays, we obtained plasma samples after 15-min rest from 88 healthy nonfasting control individuals. These controls were volunteers recruited from hospital staff. Only persons who reported being healthy (i.e., feeling well, without known diseases, and not taking any medications) were included ( Fig. 1 , gate 2 criteria). Control age and sex are shown in Table 1 .
The CgA response to a mixed meal was studied in 8 healthy volunteers (4 men and 4 women; age range, 23-50 years) after an overnight fast. Consecutive postprandial blood samples were drawn 5-180 min after ingestion of the meal and analyzed with the 4 CgA assays.
For all patients and controls the index tests were performed at the Department of Clinical Biochemistry, Rigshospitalet, between January 1999 and July 2002. The index test was carried out by 2 trained technicians and read by the same technicians and a medical specialist in clinical biochemistry. The readers of the index test knew whether the plasma samples were from healthy persons or from tumor patients and also knew the result of the reference standard. Clinical information (symptoms, scan/operation results, and medication) on the patients was made available to the medical specialist after the index test had been performed.
statistical methods
Kruskal-Wallis ANOVA, Mann-Whitney U-test (2-tailed), and Wilcoxon rank sum test were performed with GraphPad Prism 4 for Windows; version 4.03, GraphPad Software Inc. For calculating reference values and performing the Kolmogorov-Smirnov test of normality we used SPSS for Windows v.12.0, SPSS Inc. The 0.95 confidence intervals (CIs) of the 2.5th and 97.5th percentiles were calculated according to Tietz et al. (21 ) . We performed the exact binomial test to calculate 95% CIs for diagnostic sensitivity. Differences in diagnostic sensitivi- 
Results
tryptic digestion of plasma samples
Trypsin treatment of plasma increased the median CgA(3403) immunoreactivity 9-fold in controls and 6-to 16-fold in patients with neuroendocrine tumors and SCLC (Table 2 and Fig. 2 ). However, a large variation in the increase of CgA(3403) immunoreactivity was found within the tumor groups, with up to 500-fold increases found in some patients.
tryptic digestion of chromatography fractions
Size-exclusion chromatography profiles of plasma samples from patients with midgut carcinoid tumors showed that the majority of the CgA(3403) immunoreactivity eluted from a Sepharose HR 12 column with coefficients of distribution (Kds) of 0.6 -0.7. After trypsin treatment of the chromatography fractions, the majority of the posttryptic CgA immunoreactivity eluted in broad peaks (Kd 0.15-0.45, maximum 0.3) that comprised several highmolecular-weight forms, and only a minor fraction eluted corresponding to the peaks with Kds of 0.6 -0.7 (see Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol53/issue3). These results indicated that the plasma samples in which trypsination markedly increased CgA(3403) immunoreactivity contained high amounts of unprocessed or poorly processed CgA.
quantification of cga in plasma
In agreement with a previous study (23 ), meal ingestion in the controls did not lead to significant changes in plasma CgA (13) 
evaluation of diagnostic accuracy
The concentrations measured with the 4 CgA assays in the 54 plasma samples from the tumor patients and controls are shown in Table 3 and Fig. 2 . In defining the diagnostic sensitivity (the ratio of true positive to true positive plus false negative) true-positive vs true-negative designations were applied to patients with a neuroendocrine tumor diagnosis established by histopathological examination, depending on whether or not they had increased plasma CgA concentrations compared to controls. The upper limits of the reference intervals (central 95%) were used as cutoffs. The diagnostic sensitivities of tumor patients are shown for the 4 CgA assays in Table 4A . In all groups the highest diagnostic sensitivities were obtained with the CgA(3403) assay and CgA PIA. The diagnostic sensitivity obtained with the CgA(3403) assay was 1.00 for patients with local, extensive, and very extensive gastrointestinal neuroendocrine tumors. For all other assays the diagnostic sensitivities increased with increasing tumor burden (Table 4B) . However, significant differences between the diagnostic sensitivities of these groups were found only for the CgA(13) assay and the CgA PIA. Furthermore, significant differences between the diagnostic sensitivities obtained for limited and extensive SCLC were found only for the CgA(3403) assay (Fishers exact test, Table 4B ).
In the patients with gastrointestinal tumors a higher tumor burden was generally accompanied by higher concentrations of CgA(3403) and total CgA immunoreactivity, as well as a lower degree of CgA processing. Kruskal-Wallis ANOVA applied on the CgA(3403), CgA(3403) ϩ trypsin, and ratio [CgA(3403) ϩ trypsin/ CgA(3403)] results from the 3 groups of gastrointestinal tumor patients with limited (group 1), extensive (group 2), and very extensive (group 3) disease showed significant differences between the groups, P ϭ 0.009 [CgA(3403)], P ϭ 0.002 [CgA(3403) ϩ trypsin], and P ϭ 0.002 [CgA(3403) ϩ trypsin/CgA(3403)], respectively. Posthoc Mann-Whitney U-test demonstrated significant differences between group 3 vs 2, 3 vs 1 and 2, and 3 vs 1 for the 3 sets of data [CgA(3403), CgA(3403) ϩ trypsin, and CgA(3403) ϩ trypsin/CgA(3403)], whereas group 1 did not differ significantly from group 2 or from groups 2 and 3 ( Table 2) .
For the patients with SCLC, the concentrations measured with the CgA(3403) assay in plasma from patients with extensive disease (group 2) were significantly higher than the concentrations measured in patients with local disease (group 1) (Mann-Whitney U-test, Table 2 ). The corresponding concentrations measured with the CgA PIA were borderline significantly higher (P ϭ 0.06, Table  2 ).
Discussion
Our results demonstrate that both the CgA(3403) and posttryptic CgA(3403) assays have a high diagnostic sensitivity in patients with neuroendocrine tumors or SCLC. In agreement with these results, high concentrations of unprocessed CgA were found in plasma from these patients, as corroborated by size-exclusion chromatography. These results are in accordance with reports that PIA analyses have increased the diagnostic accuracy for progastrin (6, 10 ) , probrain natriuretic peptide, and rat a Plasma samples were incubated with trypsin prior to CgA(3403) assay, as described in the text. epidermal growth factor (11, 24 ) . Furthermore, a PIA for procholecystokinin has recently been found to be a valuable tool for the diagnosis and monitoring of the efficiency of chemotherapy for patients with Ewing sarcomas, and the PIA proved superior to a conventional cholecystokinin RIA (14 ) . An application of PIA for human CgA has not previously been published. The observation that the increase in CgA(3403) immunoreactivity after trypsination of plasma samples was significantly higher in plasma from patients with very extensive gastrointestinal neuroendocrine tumors (group 3) than in plasma from the patients with extensive (group 2) and local disease (group 1) ( Table 2 ) is in agreement with earlier reports (5, 8 ) in which a lower degree of processing of progastrin was found in plasma from gastrinoma patients with metastases. A low degree of progastrin processing in gastrinomas has been previously suggested to predict a malignant clinical course (8 ) , whether this could be the case for CgA from gastrointestinal tumors requires further study.
Furthermore, our finding that the concentrations measured with the CgA(3403) assay and the PIA increased with the degree of tumor/carcinoma dissemination is in agreement with a previous report (25 ) that CgA concentrations were significantly higher in plasma from midgut carcinoid tumor patients with Ն5 liver metastases than in those with Ͻ5 liver metastases. Plasma CgA has also been reported to be significantly higher in metastatic gastroenteropancreatic endocrine tumors than in nonmetastatic tumors (26 ) , and higher in patients with extensive SCLC than in patients with limited disease (27 ) . CgA plasma concentrations have also been found to correlate with tumor weight in nude mice with xenografted human ileal carcinoid tumors (28 ) . For some of the gastrointestinal neuroendocrine tumor patients with widespread, rapidly progressing disease the CgA PIA results seemed to enable better estimation of the tumor burden than the CgA(3403)assay results (results not shown). Further studies are needed to confirm this.
CgA in plasma is frequently used as a marker for neuroendocrine tumors and prostatic carcinomas. Measurements are performed with antisera raised against purified full-length CgA or large fragments from tumor patients (3, 23, 29 -36 ) , or with sequence-specific RIAs (15, 32, (37) (38) (39) . Highly variable diagnostic sensitivities occur depending on tumor type and specificity of the assay employed.
With a monoclonal antibody-based RIA used for patients with SCLC, increased concentrations were measured in 53% of patients with limited and 72% with extensive disease (40 ) . In a study using a CgA ELISA for which the antiserum was raised against a C-terminal CgA fragment purified from urine of a carcinoid tumor patient, increased concentrations were measured in 37% of patients with SCLC (27 ) . In the present study the corresponding results using the CgA(3403) assay were 100% (extensive disease) and 58% (limited disease), and using the CgA PIA 89% (extensive disease) and 67% (limited disease), respectively.
In a study using an antiserum raised against fulllength CgA on plasma samples from 208 patients with neuroendocrine tumors, increased CgA concentrations were measured in 53% of the patients, most frequently observed in the pheochromocytoma (89%) and carcinoid tumor patients (80%) (29 ) . In a similar study, plasma CgA was quantified with an RIA using an antiserum raised against C-terminal CgA fragments isolated from urine from a carcinoid tumor patient and a pancreastatin antiserum, respectively, and increased concentrations were measured in 99% with the CgA assay and in 46% with the pancreastatin assay (32 ) . In a study using an antiserum raised against CgA isolated from a pheochromocytoma, plasma CgA concentrations were increased in 81% of patients with neuroendocrine tumors (1 ) . Furthermore, with use of an immunoradiometric assay increased concentrations were found in 63% of patients with gastroenteropancreatic endocrine tumors (26 ) .
Comparison of the diagnostic sensitivities obtained with the CgA assays referred to above and the results on the CgA(3403) assay and the CgA PIA reported in this study shows that both are particularly potent and sensitive tools in the diagnosis of neuroendocrine tumors and SCLC. Whether one of the 2 assays is superior to the other requires analysis on a larger patient population. Both the CgA(3403) assay and the CgA PIA results increased with the degree of metastatic disease and may thus reflect tumor burden. The diagnostic sensitivities generally increased with the degree of metastatic disease. However, for the CgA(3403) assay the sensitivity was very high in the patients with gastrointestinal tumors, irrespective of dissemination. Further study is required to determine whether a low degree of CgA processing is a predictor of malignancy.
